VERTEX PHARMACEUTICALS INC / MA Investment Income, Interest and Dividend
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Investment Income, Interest and Dividend of $490.90 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterestAndDividend · last filed 2026-02-13
- VERTEX PHARMACEUTICALS INC / MA investment income, interest and dividend for the quarter ending 2025-12-31 was $121.90M, a 4.91% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA investment income, interest and dividend for the quarter ending 2025-09-30 was $125.70M, a 4.92% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA investment income, interest and dividend for the quarter ending 2025-06-30 was $122.40M, a 21.79% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA investment income, interest and dividend for the quarter ending 2025-03-31 was $120.90M, a 33.28% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA investment income, interest and dividend for fiscal 2025 was $490.90M, a 17.92% decline from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA investment income, interest and dividend for fiscal 2024 was $598.10M, a 2.70% decline from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA investment income, interest and dividend for fiscal 2023 was $614.70M, a 325.10% increase from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA investment income, interest and dividend for fiscal 2022 was $144.60M, a 2851.02% increase from fiscal 2021.
| Period end | Investment Income, Interest and Dividend 3 month | Investment Income, Interest and Dividend 3 month as first filed | Investment Income, Interest and Dividend 6 month | Investment Income, Interest and Dividend 6 month as first filed | Investment Income, Interest and Dividend 9 month | Investment Income, Interest and Dividend 9 month as first filed | Investment Income, Interest and Dividend 12 month | Investment Income, Interest and Dividend 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $121.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $247.60M derived: sum of 2 quarters · filed 2026-02-13 | $370.00M derived: sum of 3 quarters · filed 2026-02-13 | $490.90M 10-K · filed 2026-02-13 | ||||
| 2025-09-30 | $125.70M 10-Q · filed 2025-11-04 | $248.10M derived: sum of 2 quarters · filed 2025-11-04 | $369.00M 10-Q · filed 2025-11-04 | $497.20M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2025-06-30 | $122.40M 10-Q · filed 2025-08-05 | $243.30M 10-Q · filed 2025-08-05 | $371.50M derived: sum of 3 quarters · filed 2026-02-13 | $503.70M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2025-03-31 | $120.90M 10-Q · filed 2025-05-06 | $249.10M derived: sum of 2 quarters · filed 2026-02-13 | $381.30M derived: sum of 3 quarters · filed 2026-02-13 | $537.80M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-12-31 | $128.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $260.40M derived: sum of 2 quarters · filed 2026-02-13 | $416.90M derived: sum of 3 quarters · filed 2026-02-13 | $598.10M 10-K · filed 2026-02-13 | ||||
| 2024-09-30 | $132.20M 10-Q · filed 2025-11-04 | $288.70M derived: sum of 2 quarters · filed 2025-11-04 | $469.90M 10-Q · filed 2025-11-04 | $649.40M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-06-30 | $156.50M 10-Q · filed 2025-08-05 | $337.70M 10-Q · filed 2025-08-05 | $517.20M derived: sum of 3 quarters · filed 2026-02-13 | $685.10M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-03-31 | $181.20M 10-Q · filed 2025-05-06 | $360.70M derived: sum of 2 quarters · filed 2026-02-13 | $528.60M derived: sum of 3 quarters · filed 2026-02-13 | $673.30M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2023-12-31 | $179.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $347.40M derived: sum of 2 quarters · filed 2026-02-13 | $492.10M derived: sum of 3 quarters · filed 2026-02-13 | $614.70M 10-K · filed 2026-02-13 | ||||
| 2023-09-30 | $167.90M 10-Q · filed 2024-11-05 | $312.60M derived: sum of 2 quarters · filed 2024-11-05 | $435.20M 10-Q · filed 2024-11-05 | $521.20M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-06-30 | $144.70M 10-Q · filed 2024-08-02 | $267.30M 10-Q · filed 2024-08-02 | $353.30M derived: sum of 3 quarters · filed 2025-02-13 | $399.50M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-03-31 | $122.60M 10-Q · filed 2024-05-07 | $208.60M derived: sum of 2 quarters · filed 2025-02-13 | $254.80M derived: sum of 3 quarters · filed 2025-02-13 | $265.60M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2022-12-31 | $86.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $132.20M derived: sum of 2 quarters · filed 2025-02-13 | $143.00M derived: sum of 3 quarters · filed 2025-02-13 | $144.60M 10-K · filed 2025-02-13 | ||||
| 2022-09-30 | $46.20M 10-Q · filed 2023-11-07 | $57.00M derived: sum of 2 quarters · filed 2023-11-07 | $58.60M 10-Q · filed 2023-11-07 | $59.80M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-06-30 | $10.80M 10-Q · filed 2023-08-02 | $12.40M 10-Q · filed 2023-08-02 | $13.60M derived: sum of 3 quarters · filed 2024-02-15 | $14.70M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-03-31 | $1.60M 10-Q · filed 2023-05-02 | $2.80M derived: sum of 2 quarters · filed 2024-02-15 | $3.90M derived: sum of 3 quarters · filed 2024-02-15 | $5.00M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2021-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $2.30M derived: sum of 2 quarters · filed 2024-02-15 | $3.40M derived: sum of 3 quarters · filed 2024-02-15 | $4.90M 10-K · filed 2024-02-15 | ||||
| 2021-09-30 | $1.10M 10-Q · filed 2022-10-28 | $1.12M 10-Q · filed 2021-11-03 | $2.20M derived: sum of 2 quarters · filed 2022-10-28 | $3.70M 10-Q · filed 2022-10-28 | $3.71M 10-Q · filed 2021-11-03 | $6.02M derived: sum of 4 quarters · filed 2022-10-28 | ||
| 2021-06-30 | $1.10M 10-Q · filed 2022-08-05 | $1.13M 10-Q · filed 2021-07-30 | $2.60M 10-Q · filed 2022-08-05 | $2.60M 10-Q · filed 2021-07-30 | $4.92M derived: sum of 3 quarters · filed 2022-08-05 | $8.02M derived: sum of 4 quarters · filed 2022-08-05 | ||
| 2021-03-31 | $1.50M 10-Q · filed 2022-05-06 | $1.47M 10-Q · filed 2021-04-30 | $3.82M derived: sum of 2 quarters · filed 2022-05-06 | $6.92M derived: sum of 3 quarters · filed 2022-05-06 | $11.16M derived: sum of 4 quarters · filed 2022-05-06 | |||
| 2020-12-31 | $2.32M 10-K · filed 2021-02-11 | $5.42M derived: sum of 2 quarters · filed 2021-11-03 | $9.66M derived: sum of 3 quarters · filed 2021-11-03 | $22.20M 10-K · filed 2023-02-10 | $22.24M 10-K · filed 2021-02-11 | |||
| 2020-09-30 | $3.10M 10-Q · filed 2021-11-03 | $7.34M derived: sum of 2 quarters · filed 2021-11-03 | $19.92M 10-Q · filed 2021-11-03 | $32.28M derived: sum of 4 quarters · filed 2021-11-03 | ||||
| 2020-06-30 | $4.24M 10-Q · filed 2021-07-30 | $16.82M 10-Q · filed 2021-07-30 | $29.18M derived: sum of 3 quarters · filed 2021-07-30 | $46.81M derived: sum of 4 quarters · filed 2021-07-30 | ||||
| 2020-03-31 | $12.58M 10-Q · filed 2021-04-30 | $24.93M derived: sum of 2 quarters · filed 2021-04-30 | $42.56M derived: sum of 3 quarters · filed 2021-04-30 | $60.64M derived: sum of 4 quarters · filed 2021-04-30 | ||||
| 2019-12-31 | $12.36M 10-K · filed 2021-02-11 | $29.99M derived: sum of 2 quarters · filed 2021-02-11 | $48.06M derived: sum of 3 quarters · filed 2021-02-11 | $63.70M 10-K · filed 2022-02-09 | $63.68M 10-K · filed 2020-02-13 | |||
| 2019-09-30 | $17.63M 10-K · filed 2021-02-11 | $35.70M derived: sum of 2 quarters · filed 2021-02-11 | $51.32M 10-Q · filed 2020-10-30 | $65.29M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-06-30 | $18.08M 10-K · filed 2021-02-11 | $33.69M 10-Q · filed 2020-07-31 | $47.66M derived: sum of 3 quarters · filed 2021-02-11 | $58.20M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-03-31 | $15.62M 10-K · filed 2021-02-11 | $29.59M derived: sum of 2 quarters · filed 2021-02-11 | $40.13M derived: sum of 3 quarters · filed 2021-02-11 | $48.18M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2018-12-31 | $13.97M 10-K · filed 2020-02-13 | $24.51M derived: sum of 2 quarters · filed 2020-02-13 | $32.56M derived: sum of 3 quarters · filed 2020-02-13 | $38.35M 10-K · filed 2021-02-11 | ||||
| 2018-09-30 | $10.54M 10-K · filed 2020-02-13 | $18.59M derived: sum of 2 quarters · filed 2020-02-13 | $24.38M 10-Q · filed 2019-10-31 | |||||
| 2018-06-30 | $8.05M 10-K · filed 2020-02-13 | $13.84M 10-Q · filed 2019-08-01 | ||||||
| 2018-03-31 | $5.79M 10-K · filed 2020-02-13 | |||||||
| 2017-12-31 | $11.75M 10-K · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |